EPS for Talend S.A. (TLND) Expected At $-0.33; REGENICIN (RGIN) Shorts Down By 52.44%

May 4, 2018 - By Marguerite Chambers

REGENICIN INC (OTCMKTS:RGIN) had a decrease of 52.44% in short interest. RGIN’s SI was 23,400 shares in May as released by FINRA. Its down 52.44% from 49,200 shares previously. With 69,200 avg volume, 0 days are for REGENICIN INC (OTCMKTS:RGIN)’s short sellers to cover RGIN’s short positions. The SI to REGENICIN INC’s float is 0.02%. It closed at $0.0575 lastly. It is down 0.00% since May 4, 2017 and is . It has underperformed by 11.55% the S&P500.

Analysts expect Talend S.A. (NASDAQ:TLND) to report $-0.33 EPS on May, 10 after the close.They anticipate $0.14 EPS change or 73.68% from last quarter’s $-0.19 EPS. After having $-0.34 EPS previously, Talend S.A.’s analysts see -2.94% EPS growth. The stock increased 3.80% or $1.91 during the last trading session, reaching $52.14. About 218,116 shares traded. Talend S.A. (NASDAQ:TLND) has risen 75.95% since May 4, 2017 and is uptrending. It has outperformed by 64.40% the S&P500.

Regenicin, Inc. focuses on developing and commercializing a technology of tissue-engineered skin substitutes to restore the qualities of healthy human skin for use in the treatment of burns, chronic wounds, and various plastic surgery procedures. The company has market cap of $8.83 million. The Company’s development products include NovaDerm, a cultured skin substitute product for the treatment of burns; and TempaDerm to treat smaller wound areas on patients, such as ulcers. It currently has negative earnings. The firm was formerly known as Windstar, Inc. and changed its name to Regenicin, Inc. in July 2010.

Among 2 analysts covering Talend (NASDAQ:TLND), 1 have Buy rating, 0 Sell and 1 Hold. Therefore 50% are positive. Talend had 2 analyst reports since August 24, 2016 according to SRatingsIntel. Citigroup maintained it with “Neutral” rating and $30 target in Friday, August 26 report. William Blair initiated Talend S.A. (NASDAQ:TLND) on Wednesday, August 24 with “Outperform” rating.

Talend S.A. (NASDAQ:TLND) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter:

Recent Posts